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Introduction: XP is a very rare inherited disease affecting 1 in 250,000 people (~90 UK patients). It 
involves extreme sensitivity to UV light; the only treatment is complete avoidance of UV – not going 
outside during daylight, fitting UV screens to windows, or ensuring complete skin coverage. Most 
patients die by age 35, usually from skin cancers. No research on the psychological consequences of 
XP or factors relating to UV protection currently exists.  
Methods: In phase one, an N-of-1 study was conducted in 25 adult XP patients, as part of a mixed 
methods approach to intervention development. Participants wore a UV wristwatch and completed a 
brief survey, including adherence behaviours and psychological predictors (e.g., emotions, self-
regulation), for 50 consecutive days. Constructs were selected from the theory domains framework 
and a review of behavioural maintenance theories.  
Results: N-of-1 analysis revealed differences in the patterns of predictors of adherence across 
participants, supporting the need for an individualised approach. Following MRC guidelines, phase 
two involves the development of a series of individualised interventions to improve adherence, 
informed directly by the specific predictors identified for each participant in phase one (e.g., including 
BCTs to target motivation, planning, or emotions). After PPI feedback and piloting, the interventions 
will be tested in a waitlist-controlled RCT in a matched sample of non-adherent adults.  
Conclusions: The XP study provides a novel example of systematic intervention development in a rare 
and unstudied condition, which could be used as a model for understanding and improving health 
outcomes in other rare diseases.  
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